Topic:
Companion Diagnostics
Latest Headlines
Latest Headlines
Roche gains FDA sign-off on lung cancer companion Dx
Roche's surging diagnostics arm scored a major win this week, gaining FDA approval what is being billed as the first companion diagnostic meant to detect a specific mutation connected to metastatic non-small cell lung cancer.
Roche diagnostics division sales fall flat in Q1
Roche's diagnostics division generated mixed results in its 2013 first quarter. The Swiss drug giant generally enjoyed increased sales for its patient and laboratory tests. But the company's diabetes division continued to struggle, hammered by reimbursement cuts and tougher pricing pressures.
GE launches cancer assay with eye on companion Dx
GE Healthcare has been steadily building up its diagnostics offerings over the past three years, and now the company is launching a sequencing assay targeting solid tumors in clinical trials.
PrimeraDx teams with Quest for companion diagnostics
PrimeraDx, a 2012 Fierce 15 company, has hitched on with Quest Diagnostics to co-develop companion diagnostics, giving the company a major megaphone to attract Big Pharma deals.
Sundance sees future for companion Dx to measure drug-related suicide risk
Sundance Diagnostics is pursuing a novel path for companion diagnostics development--blood tests that will gauge a patient's risk for suicide while taking certain antidepressant drugs. The new twist: The blood tests will be paired with prescription drugs already on the market.
Merck recruits Luminex for Alzheimer's diagnostics
Merck is pressing forward with its controversial Alzheimer's treatment, and now it has signed a deal with Luminex to develop a companion diagnostic that will screen patients for its ongoing clinical program.
Dako wins companion Dx approval for Roche's Kadcyla
Dako has been on a tear with big-name companion diagnostics partnerships, and its latest one might end up being the most lucrative: The company has received FDA approval for two tests to be paired with Kadcyla, Roche's soon-to-explode breast cancer drug.
Abbott inks companion Dx deal for J&J's 'breakthrough' cancer drug
Johnson & Johnson scored a major victory with the FDA this month when the agency put its breakthrough designation on an investigational cancer drug, and now Abbott Laboratories is stepping in to develop a companion diagnostic for the headline-grabbing compound.
Lilly cozies up to Qiagen for more companion diagnostics
Eli Lilly is expanding its partnership with Qiagen, building off of past success in a new broad collaboration agreement for companion diagnostics.
Dako inks companion diagnostics deal with Pfizer
Agilent Techologies' Dako unit has added Pfizer to its list of companion diagnostics partners, signing a deal that covers the research, development and commercialization of tests to match the drugmaker's pipeline treatments.
